Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480036 | 1.00 | HDAC1 (0.70) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL7547764 | 0.99 | HDAC1 (0.69) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL7547761 | 0.97 | HDAC1 (0.67) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL25233958 | 0.89 | HDAC6 (0.64) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL6925477 | 0.85 | PTGS1 (0.65) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL6921299 | 0.85 | HDAC1 (0.69) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL6925062 | 0.84 | PTGS1 (0.58) | HDAC1HDAC6CA1CA2CSNK2A2 | |
| SCHEMBL14894467 | 0.83 | HDAC6 (1.00) | HDAC1HDAC6 | |
| SCHEMBL6755499 | 0.82 | HDAC1 (0.56) | HDAC1HDAC6CA1CA2ALB | |
| SCHEMBL14895937 | 0.82 | HDAC6 (0.75) | HDAC1HDAC6CA1CA2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066667-A1 | Nonlinear Optical Chromophores Having Tetrahydrocarbazole Donor Groups, Lyotropic Compositions Containing the Same, and Methods of Poling Such Compositions | LIGHTWAVE LOGIC, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12173217-B2 | Nonlinear optical chromophores having tetrahydrocarbazole donor groups, lyotropic compositions containing the same, and methods of poling such compositions | LIGHTWAVE LOGIC, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240247192-A1 | Nonlinear Optical Chromophores Having Tetrahydrocarbazole Donor Groups, Lyotropic Compositions Containing the Same, and Methods of Poling Such Compositions | LIGHTWAVE LOGIC, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| US-11976232-B2 | Nonlinear optical chromophores having tetrahydrocarbazole donor groups, lyotropic compositions containing the same, and methods of poling such compositions | LIGHTWAVE LOGIC, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230183575-A1 | Nonlinear Optical Chromophores Having Tetrahydrocarbazole Donor Groups, Lyotropic Compositions Containing the Same, and Methods of Poling Such Compositions | LIGHTWAVE LOGIC, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023107680-A1 | NONLINEAR OPTICAL CHROMOPHORES HAVING TETRAHYDROCARBAZOLE DONOR GROUPS, LYOTROPIC COMPOSITIONS CONTAINING THE SAME, AND METHODS OF POLING SUCH COMPOSITIONS | LIGHTWAVE LOGIC, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034895-B2 | Composition and methods for treating glioblastoma | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2606032-B1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMAS | UNIV WASHINGTON CT COMMERCIALI (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
| US-6514968-B1 | Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising | PHARMACIA & UPJOHN COMPANY | 2003-02-04 | — | — | US | disclosed |
| EP-1210329-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001017963-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | HDAC1 389/4885HDAC6 42/4885CA1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.